Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies, reported data from two clinical presentations at EASL, including rapid and profound ...

Synopsis Influenza A virus Matrix 2 protein (M2) contains a LIR motif which is cleaved by caspases at late time points of infection. Permanently truncated M2 leads to decreased filament formation, ...

In this GEN webinar, our speaker, Eric Johansen, PhD, will demonstrate the utility of virion-displayed membrane proteins for screening antibody biologics.

The nonenveloped, hollow, cylindrical virion is formed from a coiling fiber, which consists of two intertwining halves of a single circular nucleoprotein. The virus ACV is also exceptional for its ...

Proteins are so much more than nutrients in food. Virtually every reaction in the body that makes life possible involves this large group of molecules. And when things go wrong in our health, proteins ...

The evolution of SARS-CoV-2 variants has influenced viral Spike (S) protein structure and cleavage by furin, and has been proposed to modulate virion morphology. This study presents a characterization ...

Digitally-colorized electron microscopic (EM) image depicting a monkeypox virion (virus particle), obtained from a clinical sample associated with a 2003 prairie dog outbreak, published June 6, 2022.

--Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc., today announced that the ...

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection ...

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection ...

Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced ...

Virion Therapeutics, LLC, and Ocean Biomedical, Inc. today announced they have entered into a joint venture to accelerate and expand Virion's clinical-stage program and pipeline, with the goal of ...